Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 7/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21567564 | 0.79 | KMT2A (0.47) | KMT2AL3MBTL1SCDGAAATM | |
| SCHEMBL21543340 | 0.75 | SCD (0.45) | KLKB1SCDGAACYP19A1SCD5 | |
| SCHEMBL21542778 | 0.73 | ALDH1A1 (0.42) | KLKB1KMT2ASCDRIPK1SCD5 | |
| SCHEMBL25678892 | 0.71 | NPC1 (0.47) | KLKB1CYP19A1ALDH1A1MAPTAADAT | |
| SCHEMBL21543007 | 0.69 | CYP19A1 (0.44) | KLKB1L3MBTL1CYP19A1ALDH1A1MAPT | |
| SCHEMBL25680697 | 0.69 | CYP19A1 (0.44) | KLKB1L3MBTL1SCDCYP19A1SCD5 | |
| SCHEMBL19775182 | 0.63 | LMNA (0.35) | KMT2AL3MBTL1GAAMEN1ALDH1A1 | |
| SCHEMBL16789558 | 0.63 | TDP1 (0.45) | KMT2AL3MBTL1GAAATMMEN1 | |
| SCHEMBL717194 | 0.61 | CYP19A1 (0.43) | KMT2ASCDCYP19A1MEN1ALDH1A1 | |
| SCHEMBL21561746 | 0.61 | SIGMAR1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KLKB1 4275/4885KMT2A 2069/4885L3MBTL1 3825/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | KLKB1 4275/4885KMT2A 2069/4885L3MBTL1 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.